February 18, 2021 04:13 AM ESTUpdated 06:22 AM

A month after multi-billion dollar Novartis deal, BeiGene follows up with 'reverse' deal

Nicole DeFeudis

Editor

Just over a month after striking a deal with Novartis to bring its PD-1 antibody tislelizumab stateside, China-based BeiGene is making a similar play in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A month after multi-billion dollar Novartis deal, BeiGene follows up with 'reverse' deal

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Stem cell startup spun out of George Church’s lab raises $75M

Breaking down silos with a new quantitative approach to drug development

A month af­ter mul­ti-bil­lion dol­lar No­var­tis deal, BeiGene fol­lows up with 're­verse' deal

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

A month after multi-billion dollar Novartis deal, BeiGene follows up with 'reverse' deal